Positive clinical studies are not enough to justify a stock rallying this much: $ANAB, AnaptysBio, Inc. / H1 Such is the case with $ANAB stock. Plus, this AD drug developer is too early in having a drug to market. Pfizer and Regeneron dominate this space$ANAB will fall back to $40. Agree or disagree?Vote Now!